Earnings summaries and quarterly performance for Tenaya Therapeutics.
Executive leadership at Tenaya Therapeutics.
Board of directors at Tenaya Therapeutics.
Research analysts covering Tenaya Therapeutics.
Recent press releases and 8-K filings for TNYA.
Tenaya Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice and Amends Equity Incentive Plan
TNYA
Delisting/Listing Issues
Hiring
Executive Compensation
- Tenaya Therapeutics, Inc. received a letter from Nasdaq on January 28, 2026, stating that it did not meet the minimum bid price of $1.00 per share for continued listing on the Nasdaq Global Select Market, based on the 30-day period from December 12, 2025, through January 27, 2026.
- The company has a 180-calendar-day compliance period, until July 27, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.
- Effective January 26, 2026, the Board of Directors approved an amendment to the 2024 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 2,161,000, bringing the aggregate to 3,361,000 shares. These awards are intended to attract new employees.
7 days ago
Tenaya Therapeutics provides 2026 strategic priorities and clinical milestones update
TNYA
Guidance Update
New Projects/Investments
- Tenaya Therapeutics outlined its 2026 strategic priorities and anticipated clinical milestones for its gene therapy programs, TN-201 and TN-401.
- For TN-201, the company expects to share interim Cohort 2 data and Cohort 1 updates in the first half of 2026, with one-year Cohort 2 and two-year Cohort 1 data anticipated in the second half of 2026.
- For TN-401, a Data Safety Monitoring Board (DSMB) review is expected in the first quarter of 2026, followed by one-year Cohort 1 and initial Cohort 2 data in the first half of 2026.
- The company ended Q3 2025 with $56.3 million in cash, cash equivalents, and investments, and raised an additional $60 million in 4Q25, which is expected to fund operations through mid-2027.
Jan 9, 2026, 1:30 PM
Tenaya Therapeutics Prices Public Offering
TNYA
- Tenaya Therapeutics announced the pricing of an underwritten public offering of 50,000,000 units at a public offering price of $1.20 per unit, expecting gross proceeds of $60 million.
- Each unit comprises one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.50 per share, with warrants exercisable immediately and expiring five years from issuance.
- The net proceeds from the offering are intended to fund the ongoing and planned development of clinical and early-stage product candidates, specifically TN-201 and TN-401, and for working capital and other general corporate purposes.
- The offering is anticipated to close on or about December 15, 2025.
Dec 12, 2025, 5:16 AM
Tenaya Therapeutics Reports Positive Initial TN-401 Clinical Data and TN-201 Clinical Hold Lifted
TNYA
New Projects/Investments
- Tenaya Therapeutics presented positive initial data from Cohort 1 of the RIDGE-1 Phase 1b/2 clinical trial for TN-401 gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
- TN-401 demonstrated a promising safety profile, being well tolerated at the 3e13 vector genome per kilogram dose with mostly mild, manageable adverse events, and no evidence of cardiac inflammation or proarrhythmic effects.
- Biopsy results confirmed robust gene expression and a mean 10% increase in PKP2 protein levels in two of three patients by week eight.
- Clinically, significant reductions in PVC counts (46%-89%) and positive changes in non-sustained ventricular arrhythmias were observed in two patients, with one patient's NSVT burden falling to zero.
- Additionally, the FDA lifted the procedural clinical hold on the MyPEAK-1 trial for TN-201, Tenaya's gene therapy program for MYBPC3-associated hypertrophic cardiomyopathy, within approximately five weeks.
Dec 11, 2025, 10:00 PM
Tenaya Therapeutics Announces Interim Data from RIDGE-1 Trial for TN-401
TNYA
New Projects/Investments
- Tenaya Therapeutics' TN-401 gene therapy was well tolerated in Cohort 1 (3E13 vg/kg dose) of the RIDGE-1 Phase 1b/2 clinical trial, leading the Data Safety Monitoring Board (DSMB) to clear dosing for Cohort 2 (6E13 vg/kg). No TN-401-related serious adverse events (SAEs) have been reported for Cohort 2 to date.
- Biopsy results from Cohort 1 showed robust transduction in cardiomyocytes and consistent mRNA expression. PKP2 protein levels increased by an average of 10% in the first two patients by Week 8, with individual increases of 11% for Patient 1 and 9% for Patient 2.
- Clinically, the first two patients with at least six months of follow-up post-dosing demonstrated a mean reduction of 67% in Premature Ventricular Contraction (PVC) count.
- Non-sustained ventricular tachycardia (NSVT) burden was either eliminated or stable in the first two patients with at least six months of follow-up, with Patient 2 showing no NSVTs detected at the most recent visit compared to a significant burden prior to treatment.
- Tenaya plans to pursue regulatory feedback in 2026 on late-stage trial plans, with further data readouts for Cohort 1 (52-week data in mid-2026) and Cohort 2 (20+-week data in 1H 2026) expected throughout 2026.
Dec 11, 2025, 10:00 PM
Tenaya Therapeutics Announces Positive Initial Data for TN-401 Gene Therapy and Lift of Clinical Hold for TN-201
TNYA
New Projects/Investments
Guidance Update
- Tenaya Therapeutics announced positive initial data from Cohort 1 of the RIDGE-1 phase 1b/2 clinical trial for TN-401 gene therapy, which targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
- TN-401 was well tolerated at the 3e13 vector genome per kilogram dose, with the majority of related adverse events being mild and manageable.
- Biopsy data showed consistent evidence of TN-401 DNA reaching cardiomyocytes and robust RNA transcription, leading to a mean 10% increase in PKP2 protein levels in two of three patients by week eight.
- Early clinical results for TN-401 demonstrated significant reductions in premature ventricular contraction (PVC) counts, ranging from 46% to 89%, and positive changes in non-sustained ventricular arrhythmias (NSVTs) in Cohort 1 patients.
- Additionally, the FDA lifted the procedural clinical hold on Tenaya's TN-201 gene therapy program for MYBPC3-associated hypertrophic cardiomyopathy (HCM).
Dec 11, 2025, 10:00 PM
Tenaya Reports Positive Initial TN-401 Clinical Data and TN-201 Clinical Hold Lifted
TNYA
New Projects/Investments
- Tenaya presented initial data from Cohort 1 of the RIDGE-1 phase 1b/2 clinical trial for TN-401 gene therapy, indicating it was well tolerated at the 3e13 vector genome per kilogram dose.
- Biopsy results showed consistent TN-401 DNA transduction and RNA expression, with PKP2 protein levels increasing by a mean of 10% in two of three patients by week eight.
- Early clinical data demonstrated significant reductions in PVC counts (46%-89%) and positive changes in non-sustained ventricular arrhythmias (NSVTs), including one patient's NSVT burden falling from 78 per day to zero at week 32.
- The FDA lifted the procedural clinical hold on the MyPEAK-1 trial of TN-201, Tenaya's gene therapy program for MYBPC3-associated hypertrophic cardiomyopathy.
- Tenaya aims to explore opportunities for late-stage clinical development and pivotal studies for TN-401 potentially as early as 2026.
Dec 11, 2025, 10:00 PM
Tenaya Therapeutics Announces Lifting of Clinical Hold for MyPEAK-1 Trial
TNYA
New Projects/Investments
- Tenaya Therapeutics announced on December 11, 2025, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its MyPEAK-1 Phase 1b/2a clinical trial of TN-201 gene therapy.
- The clinical hold, initially placed on November 7, 2025, was resolved after the company addressed all FDA concerns and agreed upon protocol amendments to standardize patient monitoring and immunosuppression regimen management.
- Tenaya Therapeutics plans to resume dosing once the protocol changes are implemented at trial sites and does not expect the hold to impact data milestones or development timelines for TN-201.
Dec 11, 2025, 9:11 PM
Tenaya Therapeutics Announces Proposed Public Offering
TNYA
- Tenaya Therapeutics announced its intent to offer and sell units consisting of common stock and warrants to purchase shares of common stock.
- The company may also sell pre-funded units, which include pre-funded warrants to purchase common stock at a price of $0.001 per share and warrants to purchase common stock.
- Leerink Partners and Piper Sandler are acting as joint bookrunning managers for the proposed offering.
- The proposed offering is subject to market and other conditions, and there is no assurance as to its completion, actual size, or terms.
Dec 11, 2025, 9:02 PM
Tenaya Therapeutics Reports Positive Interim Data for TN-401 Gene Therapy
TNYA
New Projects/Investments
- Tenaya Therapeutics announced positive interim data from Cohort 1 of its RIDGE™-1 Phase 1b/2 clinical trial for TN-401 gene therapy, indicating it was well tolerated at the 3E13 vg/kg dose with no dose-limiting toxicities observed.
- The trial demonstrated robust transduction and expression of TN-401, with PKP2 protein levels increasing by a mean of 10% from baseline in two of three patients by Week 8.
- Clinically meaningful reductions in arrhythmia burden were observed in the first two patients with over six months of follow-up, including a 46% decrease in PVCs for Patient 1 and an 89% decrease in PVCs for Patient 2, whose non-sustained ventricular tachycardia (NSVT) burden also dropped from 78 counts to zero.
- Enrollment and dosing are complete for Cohort 2 (6E13 vg/kg dose), and no new serious adverse events related to TN-401 have been reported in this cohort to date.
Dec 11, 2025, 9:01 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more